DeepMed Research

Commons, Marty

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Drug-drug Interaction Study of Ganaplacide and Lumefantrine With Midazolam, Repaglinide, Dextromethorphan, Metformin, Rosuvastatin and Dolutegravir

Phase 1

Completed

Conditions: Malaria

Interventions: Drug: Midazolam
Drug: Rosuvastatin
Drug: Repaglinide
Drug: Dolutegravir
Drug: Dextromethorphan
Drug: Metformin
Drug: Ganaplacide
Combination Product: Lumefantrine

First Posted Date: 2022-02-11

Last Posted Date: 2022-11-04

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 48

Registration Number: NCT05236530

Locations: 🇬🇧
Novartis Investigative Site, Belfast, Northern Ireland, United Kingdom

Open-label Extension Study of Efficacy, Safety and Tolerability of Secukinumab in Patients With Active Lupus Nephritis

Phase 3

Terminated

Conditions: Lupus Nephritis

Interventions: Drug: Secukinumab

First Posted Date: 2022-02-10

Last Posted Date: 2025-05-16

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 31

Registration Number: NCT05232864

Locations: 🇻🇳
Novartis Investigative Site, Ho Chi Minh, VNM, Vietnam

A Masked, Placebo-controlled Study to Assess Iptacopan in Age-related Macular Degeneration

Phase 2

Recruiting

Conditions: Age-Related Macular Degeneration

Interventions: Drug: Placebo
Drug: Iptacopan (LNP023)

First Posted Date: 2022-02-09

Last Posted Date: 2024-06-25

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 146

Registration Number: NCT05230537

Locations: 🇺🇸
Southwest Retina Research Center, Durango, Colorado, United States
🇺🇸
Advanced Research LLC Research, Deerfield Beach, Florida, United States
🇺🇸
Advanced Research LLC, Deerfield Beach, Florida, United States

and more 23 locations

Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Glycopyrronium (Bromide) in Children (6 to Less Than 12 Years) With Asthma

Phase 2

Recruiting

Conditions: Asthma

Interventions: Drug: Glycopyrronium bromide 25ug
Drug: Placebo
Drug: Glycopyrronium bromide 12.5ug

First Posted Date: 2022-02-03

Last Posted Date: 2024-12-31

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 42

Registration Number: NCT05222529

Locations: 🇬🇧
Novartis Investigative Site, Stoke-on-Trent, United Kingdom

Managed Access Programs for LNP023, Iptacopan

Conditions: C3 Glomerulopathy (C3G)
Paroxysmal Nocturnal Hemoglobinuria (PNH)

First Posted Date: 2022-02-03

Last Posted Date: 2024-10-28

Lead Sponsor: Novartis Pharmaceuticals

Registration Number: NCT05222412

Managed Access Programs for PKC412, Midostaurin

Conditions: FMS-Like Tyrosine Kinase 3 (FLT3)-Mutated Acute Myeloid Leukemia
Acute Myeloid Leukemia
Aggressive Systemic Mastocytosis
Mast Cell Leukemia
Systemic Mastocytosis With an Associated Hematologic Neoplasm

First Posted Date: 2022-02-02

Last Posted Date: 2024-06-28

Lead Sponsor: Novartis Pharmaceuticals

Registration Number: NCT05219266

A 24-week Prospective, Open-label, Multicenter, Single-arm rPMS Study in Real-world Setting for Atectura®

Recruiting

Conditions: Asthma

Interventions: Other: Atectura inhalation capsule (150/80ug)
Other: Atectura inhalation capsule (150/160ug)
Other: Atectura inhalation capsule (150/320ug)

First Posted Date: 2022-02-01

Last Posted Date: 2025-01-14

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 600

Registration Number: NCT05217810

Locations: 🇰🇷
Novartis Investigative Site, Daegu, Dalseo Gu, Korea, Republic of

Special Drug Use-results Survey to Evaluate Safety and Efficacy of Cosentyx in Pediatric Patients With PsV, PsA, or GPP

Completed

Conditions: Psoriasis Vulgaris
Psoriatic Arthritis
Pustular Psoriasis

Interventions: Other: Cosentyx

First Posted Date: 2022-01-31

Last Posted Date: 2025-03-04

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 36

Registration Number: NCT05215561

Locations: 🇯🇵
Novartis Investigative Site, Wakayama, Japan

Study to Demonstrate the Efficacy and Safety of Secukinumab up to 224 Weeks in Subjects With Active Peripheral Spondyloarthritis (pSpA).

Phase 3

Withdrawn

Conditions: Active Peripheral Spondyloarthritis (pSpA)

Interventions: Biological: Secukinumab
Other: Placebo

First Posted Date: 2022-01-25

Last Posted Date: 2023-01-09

Lead Sponsor: Novartis Pharmaceuticals

Registration Number: NCT05206591

Multiple Ascending Dose Study of MHS552 in Adults Participants With Systemic Lupus Erythematosus (SLE)

Phase 1

Terminated

Conditions: Lupus Erythematosus, Systemic

Interventions: Drug: MHS552
Drug: Placebo

First Posted Date: 2022-01-24

Last Posted Date: 2024-10-09

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 8

Registration Number: NCT05203419

Locations: 🇩🇪
Novartis Investigative Site, Berlin, Germany

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy